FREMONT, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage
biopharmaceutical company, today announced that it will host a conference call and webcast on Thursday, March 14, 2019 at 4:30 p.m.
ET to discuss financial results for the fourth quarter and full year of 2018 and provide an operational and strategic update.
The Company will announce its financial results for this period in a press release to be issued prior to the call.
To access the live webcast, please visit the Investor Relations page of the Zosano Pharma website at
http://ir.zosanopharma.com/events.cfm. Alternatively, you may access the live conference call by dialing (844) 379-5311 (U.S.) or
(209) 905-5963 (international). The conference ID number is 9986631.
A replay will be available on the company's website approximately three hours after the call and available through April 14,
2019.
About Zosano Pharma
Zosano Pharma Corporation is a clinical stage biopharmaceutical company focused on providing administration of therapeutics to
patients using its intracutaneous delivery system, which consists of titanium microneedles coated with drug that can enable rapid
systemic administration to patients. The company’s lead product candidate is QtryptaTM (M207), which is Zosano’s
proprietary formulation of zolmitriptan delivered via its intracutaneous delivery technology for the treatment of migraine
disease. In February 2017, the company announced statistically significant results from the ZOTRIP pivotal study and in
February 2019, Zosano announced the completion of the final milestone in its long-term safety study and its expectations to file an
NDA for Qtrypta in the fourth quarter of 2019. Learn more at www.zosanopharma.com.
Zosano Contact:
Greg Kitchener
Chief Financial Officer
510-745-1200
PR Contact:
Sylvia Wheeler (or Alexandra Santos)
swheeler@wheelhouselsa.com/asantos@wheelhouselsa.com
